KENILWORTH, N.J.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24MRK&src=ctag" target="_blank"gt;$MRKlt;/agt; lt;a href="https://twitter.com/hashtag/MRK?src=hash" target="_blank"gt;#MRKlt;/agt;–Merck [NYSE:MRK], known as MSD outside the United States and Canada,
today announced the completion of its acquisition of Antelliq
Corporation from funds advised by BC Partners. Today’s announcement
positions the company as a global leader in animal health digital
tracking, traceability and monitoring technology and complements the
existing portfolio of vaccines and pharmaceuticals. Antelliq will be an
operating unit within Merck Animal Health.
“The animal health industry is rapidly evolving with revolutionary
digital solutions to manage the health and well-being of livestock and
companion animals with animal identification, animal monitoring and
smart data management as critical components of this technology,” said
Rick DeLuca, president, Merck Animal Health. “Through our commitment to
the Science of Healthier Animals®, we are dedicated to advancing
the health and well-being of animals and the people who take care of
them. We are excited to take this step forward with Antelliq and its
brands, Allflex Livestock Intelligence, Sure Petcare and Biomark, as we
add market-leading technology and services, which extend the range of
solutions we can provide to our customers.”
Jean-Baptiste Wautier, partner at BC Partners, commented, “We are proud
of Antelliq’s transformation over the past five years and believe that
Merck is an ideal partner to work with Antelliq’s dynamic leadership
team to support the next stage of its growth. As a truly innovative
market leader, Antelliq has significant potential to continue
spearheading development in the industry, as the use of intelligence,
data and technology play an increasingly important role in animal health
and care.”
About Merck
For more than a century, Merck, a leading global biopharmaceutical
company known as MSD outside of the United States and Canada, has been
inventing for life, bringing forward medicines and vaccines for many of
the world’s most challenging diseases. Through our prescription
medicines, vaccines, biologic therapies and animal health products, we
work with customers and operate in more than 140 countries to deliver
innovative health solutions. We also demonstrate our commitment to
increasing access to health care through far-reaching policies, programs
and partnerships. Today, Merck continues to be at the forefront of
research to advance the prevention and treatment of diseases that
threaten people and communities around the world – including cancer,
cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease
and infectious diseases including HIV and Ebola. For more information,
visit www.merck.com
and connect with us on Twitter, Facebook, Instagram,
YouTube
and LinkedIn.
About Antelliq
Antelliq is the world’s leading animal intelligence group, providing
world-class devices for animal identification, monitoring, and
traceability. Our pioneering monitoring solutions deliver smart data
products and services for the management and wellbeing of livestock,
fish and pets. For over 60 years we have been satisfying customer needs
in over 100 countries, supported by 22 production sites, spanning five
continents. Antelliq has four regional innovation centers and many
brands working collaboratively to address some of the world’s most
pressing challenges: supporting farmers with real-time actionable
information, providing a deeper connection with pets, and supporting
conservation. Across Antelliq, our different brands provide the
technology and intelligence that will be at the heart of overcoming
these challenges. The name Antelliq is the embodiment of everything we
stand for: intelligence connecting animals and people. For more
information, visit www.antelliq.com.
About BC Partners
BC Partners is a leading international investment firm with over €20
billion of assets under management in private equity, private credit and
real estate. Established in 1986, BC Partners has played an active role
in developing the European buy-out market for three decades. Today, BC
Partners executives operate across markets as an integrated team through
the firm’s offices in North America and Europe. Since inception, BC
Partners has completed 105 private equity investments in companies with
a total enterprise value of €130 billion and is currently investing its
tenth private equity fund. For more information, please visit www.bcpartners.com.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the
“company”) includes “forward-looking statements” within the meaning of
the safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These statements are based upon the current beliefs
and expectations of the company’s management and are subject to
significant risks and uncertainties. There can be no guarantees with
respect to pipeline products that the products will receive the
necessary regulatory approvals or that they will prove to be
commercially successful. If underlying assumptions prove
inaccurate or risks or uncertainties materialize, actual results may
differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry
conditions and competition; general economic factors, including interest
rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation in the
United States and internationally; global trends toward health care cost
containment; technological advances, new products and patents attained
by competitors; challenges inherent in new product development,
including obtaining regulatory approval; the company’s ability to
accurately predict future market conditions; manufacturing difficulties
or delays; financial instability of international economies and
sovereign risk; dependence on the effectiveness of the company’s patents
and other protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause results
to differ materially from those described in the forward-looking
statements can be found in the company’s 2018 Annual Report on Form 10-K
and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Contacts
Merck Media:
Noreen Verbrugge
+ 1 973-937-5450
Noreen.Verbrugge@merck.com
Pam
Eisele
+1 267-305-3558
Pamela.Eisele@merck.com
Merck
Investors:
Michael DeCarbo
+ 1 908-740-1807
Michael.decarbo@merck.com
Teri
Loxam
+ 1 908-740-1986
Teri.loxam@merck.com
Antelliq
Media:
Piers Hampson
+ 44 (0) 1954 266 001
P.hampson@surepetcare.com
Prosek
Partners (BC/Antelliq)
+44 (0)20 3878 8560
Pro-bcpartners@prosek.com